Global Immunochemistry Market

1 INTRODUCTION OF GLOBAL IMMUNOCHEMISTRYMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL IMMUNOCHEMISTRYMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL IMMUNOCHEMISTRY MARKET, BY END USER
5.1 Hospitals and Diagnostic Laboratories
5.2 Research Institutes
5.3 Other End Users

6 GLOBAL IMMUNOCHEMISTRY MARKET, BY APPLICATION
6.1 Diagnostics
6.1.1 Cancer
6.1.2 Infectious Diseases
6.1.3 Cardiovascular Disease
6.1.4 Autoimmune Diseases
6.1.5 Diabetes Mellitus
6.1.6 Nephrological Diseases
6.2 Drug Testing

7 GLOBAL IMMUNOCHEMISTRY MARKET, BY PRODUCT
7.1 Antibodies
7.1.1 Primary Antibodies
7.1.2 Secondary Antibodies
7.2 Equipment
7.2.1 Slide Staining Systems
7.2.2 Tissue Microarrays
7.2.3 Tissue Processing Systems
7.2.4 Slide Scanners
7.2.5 Other Equipment
7.3 Reagent
7.3.1 Histological Stains
7.3.2 Blocking Sera and Reagents
7.3.3 Chromogenic Substrates
7.3.4 Fixation Reagents
7.3.5 Stabilizers
7.3.6 Organic Solvents
7.3.7 Proteolytic Enzymes
7.3.8 Diluents
7.4 Kits

8 GLOBAL IMMUNOCHEMISTRYMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL IMMUNOCHEMISTRYMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 F. Hoffmann-LA Roche AG
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Danaher Corporation
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Agilent Technologies, Inc.
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Thermo Fisher Scientific Inc.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Merck Millipore
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Bio-Rad Laboratories, Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Perkinelmer, Inc.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Abcam PLC
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 LCell Signaling Technology, Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Bio SB
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

11 Appendix
11.1 Related Reports